ArticleTherapeutic advances in medical oncology2022

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.